Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Purpose. Dyslipidemia (DL) is a critical comorbidity after renal transplantation and can arise cardiovascular diseases. The relationship between developing of DL and glucocorticoid receptor (NR3C1) polymorphism was reported by the authors, previously. In this study, we validated clinical meaning of NR3C1 Bcl I G allele and assessed risk factor for developing DL and graft survival. Methods. Two hundred forty-seven consequent renal allograft recipients (153 males and 94 females) who underwent transplanted between February 2002 and September 2015 were analyzed. Susceptibility of DL was validated in 76 recipients who were transplanted from September 2011 to September 2015. Risk factors of having DL and allograft prognosis were assessed in all 247 patients. Results. In the validation study, the frequencies of DL were significantly higher in patients with the NR3C1 Bcl I G allele than in those with the CC genotype (p = 0.009). After validation, ninety-two recipients (37.2%) were diagnosed with DL after transplantation in all recipients. A relationship was observed between DL and mTOR inhibitor, female gender, and older age (p = 0.001, 0.002, and 0.026, respectively). The frequencies of DL were significantly higher in patients with the NR3C1 Bcl I G allele than in those with the CC genotype (p = 0.002). A multivariate analysis revealed that the NR3C1 receptor Bcl I G allele, mTOR inhibitor, female gender, and age older than 45 year-old was a significant risk factor for developing DL (odds ratio 2.28, 3.60, 2.63, and 2.00; 95% confidence interval, 1.28 – 4.03, 1.68 – 7.70, 1.48 – 4.69, and 1.07 – 3.26, respectively). The propensity score-matched analysis indicated 77 matched pairs from both groups, but there were no differences in graft survival between the groups. Conclusions.The NR3C1 Bcl I G allele, using mTOR inhibitor, female gender, and older age may allow for predicting the occurrence of DL. These findings may aid in predicting a patient's risk of developing DL and promoting precision immunosuppression.
CITATION INFORMATION: Numakura K., Kagaya H., Komine N., Yamamoto R., Fujiyama N., Tsuruta H., Maeno A., Saito M., Narita S., Inoue T., Niioka T., Miura M., Habuchi T., Satoh S. Glucocorticoid Receptor Polymorphism Affects Susceptibility of Dyslipidemia in Recipients One Year after Kidney Transplantation Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Numakura K, Kagaya H, Komine N, Yamamoto R, Fujiyama N, Tsuruta H, Maeno A, Saito M, Narita S, Inoue T, Niioka T, Miura M, Habuchi T, Satoh S. Glucocorticoid Receptor Polymorphism Affects Susceptibility of Dyslipidemia in Recipients One Year after Kidney Transplantation [abstract]. https://atcmeetingabstracts.com/abstract/glucocorticoid-receptor-polymorphism-affects-susceptibility-of-dyslipidemia-in-recipients-one-year-after-kidney-transplantation/. Accessed October 29, 2020.
« Back to 2018 American Transplant Congress